Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T6288 |
Mozavaptan
莫扎伐坦,OPC31260l,OPC-31260 |
Vasopressin Receptor | GPCR/G Protein |
Mozavaptan (OPC-31260) 是 benzazepine 衍生物,是一种竞争性加压素受体拮抗剂,作用于 V1 和 V2 受体,IC50 分别为 1.2 μM 和 14 nM。它可在体内拮抗精氨酸加压素的抗利尿作用,可用于低钠血症、抗利尿激素不适当综合征和充血性心力衰竭的研究。 | |||
T64174 |
Vasopressin V2 receptor antagonist 1
|
||
Vasopressin V2 receptor antagonist 1 (Compound 4g) 是一种 vasopressin V2receptor (V2R) 拮抗剂 (Ki: 3.8 nM)。Vasopressin V2 receptor antagonist 1 可以用于研究常染色体显性多囊肾病 (ADPKD)。 | |||
T7303 |
LIXIVAPTAN
VPA-985,利伐普坦,WAY-VPA 985 |
Vasopressin Receptor | GPCR/G Protein |
Lixivaptan (VPA-985) 是一种具有口服活性的选择性加压素受体 V2 拮抗剂,对人和大鼠的IC50值分别为 1.2 和 2.3 nM。 | |||
T6453 |
Conivaptan hydrochloride
Vaprisol,盐酸考尼伐坦,Conivaptan HCl,YM 087 |
Vasopressin Receptor | GPCR/G Protein |
Conivaptan hydrochloride (Vaprisol) 是一种口服有效的加压素 V2 和 V1A 受体拮抗剂,用于治疗高血容量性低钠血症和正常血容量。 | |||
T15273 |
Fedovapagon
VA483,A106483 |
Vasopressin Receptor | GPCR/G Protein |
Fedovapagon (VA106483) 是一种具有选择性和高效性的加压素 V2 受体 (V2R) 激动剂,可抑制斑马鱼节间血管的生长。Fedovapagon 可用于研究膀胱过度活动症、夜尿症和膀胱疼痛综合征。 | |||
T2326 |
Tolvaptan
托伐普坦,OPC-41061 |
Vasopressin Receptor; Autophagy | Autophagy; GPCR/G Protein |
Tolvaptan (OPC-41061) 是一种可口服的选择性精氨酸加压素受体 2 拮抗剂,可用于治疗低钠血症。 | |||
T5144 |
Desmopressin acetate (16679-58-6 free base)
Desmopressin acetate,醋酸去氨加压素,DDAVP |
Vasopressin Receptor | GPCR/G Protein |
Desmopressin acetate (16679-58-6 free base) (DDAVP) 是抗利尿激素精氨酸加压素的合成类似物。 | |||
TP2082L |
d[Cha4]-AVP acetate(500170-27-4 free base)
|
Vasopressin Receptor | GPCR/G Protein |
d[Cha4]-AVP acetate(500170-27-4 free base) 是一种有效的选择性人血管加压素 V1B 受体激动剂(V1B、V1A、催产素和 V2 受体的 Ki 值分别为 1.2、151、240 和 750 nM)。刺激 ACTH 和皮质酮分泌,并在体内表现出微不足道的血管加压活性。 | |||
T28629 |
RWJ 676070
RWJ676070,RWJ-676070 |
||
RWJ 676070 is an antagonist of vasopressin V1A/V2 receptor. | |||
T24759 |
Satavaptan fumarate
SR-121463A,SR 121463 A,SR-121463 A,SR121463A |
||
Satavaptan fumarate is a selective antagonist of the non-peptide vasopressin V2 receptor. | |||
T28664 |
Satavaptan
SR121463,SR 121463,SR-121463 |
||
Satavaptan is a vasopressin V2 receptor antagonist. Satavaptan improves the control of ascites in cirrhosis. | |||
T17251 |
VNA-932
WAY-VNA 932 |
Others | Others |
VNA-932 is an agonist of the vasopressin V2-receptor (IC50: 80.3 nM and 778 nM in human-V2 binding and V1a binding assay). | |||
T29178 |
YM 471
YM-471,YM471 |
||
YM 471 is a non-peptide arginine vasopressin (AVP) V1A and V2 receptor antagonist with oral activity. | |||
T27965 |
M-0002
RWJ-351647,SPD556,SPD-556,M0002,RWJ351647 |
||
M-0002, a vasopressin V2 receptor antagonist, is used potentially for the treatment of ascites. | |||
T24370 |
L-368899 free base
L 368899,L 368,899,L368,899,L-368899,L368899,L-368,899 |
||
L-368899 is a non-peptide and orally active antagonist of oxytocin receptor (IC50: 8.9 nM). It displays 40-fold selectivity over vasopressin V1a and V2 receptors (IC50: 370 and 570 nM respectively). | |||
T62906 |
Lazuvapagon
|
||
Lazuvapagon 是一种血管加压素 V2 受体激动剂,能够用于研究遗尿症。 | |||
TP1927 |
d[Leu4,Lys8]-VP
|
||
Selective vasopressin V1B receptor agonist (Ki values are 0.16, 64, 100 and 3800 nM for V1B, oxytocin, V2 and V1A receptors respectively). Displays weak antidiuretic, vasopressor and in vitro oxytocic activities. | |||
T16934 |
SRX246
|
Others | Others |
SRX246 has no interaction at V1b and V2 receptors. SRX246 shows negligible binding at 64 other receptors classes, including 35 G-proteincoupled receptors. SRX246 is a potent and CNS-penetrant vasopressin 1a (V1a) receptor antagonist (Ki=0.3 nM for human V | |||
TP2082 |
d[Cha4]-AVP
|
||
Potent and selective human vasopressin V1B receptor agonist (Ki values are 1.2, 151, 240 and 750 nM for V1B, V1A, Oxytocin and V2 receptors respectively). Stimulates ACTH and corticosterone secretion and exhibits negligible vasopressor activity in vivo. | |||
T21378 |
Conivaptan
YM087,YM-087,YM 087,Vaprisol |
||
Conivaptan, a non-peptide inhibitor of antidiuretic hormone, was approved for hyponatremia caused by the syndrome of inappropriate antidiuretic hormone (SIADH), there is also some evidence that it may be effective in heart failure. Conivaptan inhibits sub | |||
T75933 |
d[Cha4]-AVP TFA
|
||
d[Cha4]-AVP TFA 是一种有效的选择性加压素 (AVP)V1b 受体激动剂,对人V1b 受体的Ki 为 1.2 nM。d[Cha4]-AVP TFA 对 V1b 受体的选择性高于对人类 V1a 受体、V2 受体和催产素受体。 | |||
T14498 |
Barbadin
|
Arrestin | GPCR/G Protein |
Barbadin 是一种新型且具有特异性的 β-arrestin/β2-adaptin 相互作用抑制剂,对β-arestin1 的 IC50 值为 19.1 μM,对β-arestin2 的 IC50 值为 15.6 μM。Barbadin 增强氯卡色林对 POMC 神经元和减肥的长期影响,可阻断激动剂促进的原型 β2-肾上腺素能、V2-血管加压素和血管紧张素-II-1 型受体的内吞,可用于研究肥胖。 |